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Abstract 
Purpose: A fluorogenic peptide probe-immobilized diagnostic kit was used to analyze MMP 
activity in the synovial fluids (SFs) from patients with osteoarthritis (OA) and acute inflam-
matory conditions of the knee joint. 
Methods: The MMP diagnostic kit containing a polymer-conjugated MMP probe immobilized 
on a 96-well plate was utilized for high-throughput screening of MMP activity in SFs from OA 
patients (n = 33) and patients with acute inflammatory conditions of the knee joint (n = 5). 
Results: Compared to SF from OA patients, SF from patients with acute inflammatory 
conditions  of  the  knee  joint  presented  stronger  NIR  fluorescent  signals.  In  gelatin  zy-
mography, most samples from patients with acute inflammatory conditions of the knee joint 
also displayed 92 kDa (pro-form) MMP-9 and faint 84 kDa (active form) MMP-9, while SF from 
OA patients did not display detectable MMP-9 activity . 
Conclusion: The presence of a strong fluorescence signal from the MMP diagnostic kit 
corresponded well with patients with acute inflammatory conditions of the knee joint. The 
results suggest that our MMP diagnostic kit can be useful in differentiation between early 
stages of OA and acute inflammatory conditions of the knee joint. 
Key  words:  Matrix  metalloproteinases,  Osteoarthritis,  Synovial  fluid,  Diagnostic  kit,  Acute  in-
flammatory conditions of the knee joint 
Introduction 
Osteoarthritis (OA) is the most common degen-
erative  joint  disease,  and  affects  about  12%  of  the 
population [1]. OA is a chronic, disabling disease in-
volving  progressive  cartilage  destruction  accompa-
nied by intractable pain, and most frequently occurs 
in  the  knee  joint.  Abnormal  mechanical  injury  and 
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stress from repeated impact loading on the joint are 
involved in the progression of OA. Digestive prote-
ases are detected in larger amounts in OA cartilage 
than in normal cartilage [2, 3]. Current diagnosis of 
OA mainly focuses on two major points. The clinician 
must first differentiate OA from other types of arthri-
tis. It is also important to determine whether a patient 
has primary OA or a secondary form of OA that is 
associated with other diseases.  
OA progression is currently diagnosed by phys-
ical examination, various imaging studies, and labor-
atory tests. Any symptoms associated with OA, such 
as  joint  effusion,  tenderness,  crepitation,  decreased 
range of motion, and alignment of the knee joints, are 
carefully evaluated by physician.  Radiographs typi-
cally show joint space narrowing, subchondral scle-
rosis,  marginal  osteophytes,  and,  sometimes,  sub-
chondral cyst formation [4]. In diagnosis of OA, la-
boratory tests (e.g. blood analysis and synovial fluid 
analysis)  are  not  routinely  requested  by  physicians 
because there are no specific biologic markers for OA. 
When  OA  patients  complain  about  joint  effusions 
combined with unusual pain, differential diagnosis is 
mandatory  in order to rule out acute inflammatory 
conditions,  such  as  gout,  rheumatoid  arthritis,  pyo-
genic arthritis, or joint effusions secondary to trauma 
that  violate  intra-articular  structures  of  the  joints. 
There are several differential diagnostic methods for 
use in ruling out acute inflammatory conditions with 
OA;  however,  many  of  these  laboratory  tests  and 
imaging  studies  are  significantly  time-consuming. 
Due to its insignificant change on radiographs, accu-
rate diagnosis of joint effusion combined with early 
stages  of  OA  using  conventional  methods  in  the 
out-patient clinic is difficult [5, 6]. In addition, diag-
nosis of early stage OA, especially accompanying joint 
effusion, can be confused with joint effusion caused 
by traumatic knee joint injury, such as anterior cruci-
ate ligament rupture and/or meniscus tear. Because 
X-rays provide no information, additional studies are 
recommended, including joint fluid aspirate analyses 
or  MRIs,  which  are  time-consuming  and  additional 
economic burdens to patients. Ready availability of a 
specific  biological  marker  for  OA  at  the  bedside 
would  allow  more  individual  patient-customized 
therapy [7, 8].  
Among  various  biological  markers  associated 
with  OA,  matrix  metalloproteinases  (MMPs)  play  a 
primary role in cartilage degradation in human joint 
disease  and  function  downstream  of  OA  signaling 
pathways [9, 10]. Following excretion from the cell as 
inactive pro-forms, MMPs are activated into the active 
enzyme, which can be inhibited by reversible binding 
with  specific inhibitors, tissue inhibitors  of metallo-
proteinases  (TIMPs)  [11].  Activation  of  MMPs  is 
closely related to cartilage degradation. One or more 
MMPs can digest most of the matrix components in 
vitro [12]. Elevated levels of MMPs are found in OA 
cartilage at the site of cartilage destruction and spe-
cific digested parts of MMPs are present in SF samples 
from OA patients [13]. MMP-2 and -9 are especially 
important in cartilage degradation because they can 
degrade  a  variety  of  collagens,  including  basement 
membrane, type V collagen, and denatured fibrillar 
type I collagen [14, 15]. MMPs could  potentially be 
used as a promising biological marker of OA.  
 Several methods have been used for detection of 
MMP activity in OA SF. These methods include en-
zyme-linked  immunosorbent  assay  (ELISA),  gelatin 
zymography, and Western blotting. ELISA has been 
frequently used for measurement of total amounts of 
pro-form MMPs plus MMP-TIMP complexes, where-
as measurement of MMP in the active form is more 
appropriate in assessment of the potential of matrix 
degradation from MMPs [11]. In terms of sensitivity, 
gelatin zymography and Western blotting are supe-
rior  in  their  detection  of  MMPs;  however,  due  to 
time-consuming and cumbersome practices, they are 
unsuitable  for  rapid  high-throughput  screening  of 
larger samples.  
Previously, we developed a new MMP diagnos-
tic kit for high-throughput screening of MMP bioac-
tivity  using  polymeric  MMP  probes  [16].  Polymeric 
MMP  probes  chemically  conjugated  onto  the  plate 
surface exhibited their excellent fluorogenicity against 
target MMPs. In this study, we analyzed MMP activ-
ity in SF samples from patients with OA and acute 
inflammatory conditions of the knee joints using our 
MMP diagnostic kit, and compared the results with 
those of gelatin zymography and Western blotting. 
Materials and methods 
Harvesting Synovial Fluids 
 OA of the knee joint was diagnosed by physical 
and radiological evaluations based on the American 
College  of  Rheumatology  criteria  [17].  OA  patients 
were  subdivided  into  four  groups  according  to  the 
severity  of  disease  progression  based  on  the 
Kellgren–Lawrence Grading Scale: Grade 1: doubtful 
narrowing  of  joint  space  and  possible  osteophytic 
lipping,  Grade  2:  definite  osteophytes,  definite  nar-
rowing  of  joint  space,  Grade  3:  moderate  multiple 
osteophytes, definite narrowing of joint space, some 
sclerosis  and  possible  deformity  of  bone  contour, 
Grade 4: large osteophytes, marked narrowing of joint 
space, severe sclerosis and definite deformity of bone 
contour  [18].  Grades  of  OA  were  separately  scored Theranostics 2012, 2(2) 
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and statistically confirmed by three physicians using a 
cross-validation method. All of the patients enrolled 
in the study complained of joint pain and noticeable 
joint effusions. Prior to aspiration of the joint fluids, 
informed consents were obtained from each  patient 
according  to  the  approved  recommendation  of  the 
institutional review board (IRB) of the Korea Univer-
sity College of Medicine. SFs were aspirated from the 
knee joint of these patients in order to relieve their 
symptoms and the aspirates were aliquoted in 2 ml 
samples  and  stored  at  -70
C  prior  to  use.  SFs  were 
diluted  with  phosphate  buffered  saline  (PBS)  of 
pre-optimized  quantity  for  respective  experiments 
and  centrifuged  at  10,000g  for  10min  at  4
C  for  re-
moval of any flocculate components. 
Preparation of the matrix metalloproteinase 
diagnostic kit  
The  MMP  diagnostic  kit  was  prepared  by  im-
mobilization of a polymer-conjugated MMP peptide 
probe onto each well of a maleic anhydride-activated 
96-well plate (Pierce), as previously described [16]. In 
summary, for construction of the MMP diagnostic kit, 
first, MMP peptide probes consisting of near infrared 
(NIR)  fluorochrome,  Cy5.5  (ex/em;  675/695  nm), 
MMP-2,9,13 substrate peptides (Gly-Pro-Leu-Gly-Val- 
Arg(pbf)-Gly-Lys(boc)-Gly-Gly, the cleavage site be-
tween  Gly  and  Val),  and  black  hole  quencher-3 
(BHQ-3, abs. 650 nm) were chemically conjugated to 
glycol  chitosan  (GC)  polymers,  resulting  in  poly-
mer-conjugated  MMP  peptide  probes  [19].  Second, 
the  polymer-conjugated  MMP  peptide  probes  were 
effectively  immobilized  onto  each  well  of  a  maleic 
anhydride-activated  96-well  plate,  resulting  in  an 
MMP diagnostic kit. 
Enzyme specificity of the polymer-conjugated 
MMP peptide probe 
 Specificity  of  the  polymer-conjugated  MMP 
peptide probe was examined by incubation with ac-
tivated  MMP-2,  MMP-3,  MMP-7,  MMP-9,  and 
MMP-13, as previously described [11]. In summary, 
the polymer-conjugated MMP peptide probe (20 nM) 
was examined by incubation in the reaction buffer (50 
mM TRIZMA·HCl, 10 mM CaCl2·2H2O, 0.15 M NaCl, 
and 0.05 % Brij35, pH 7.8) containing 15nM of acti-
vated MMP-2, MMP-3, MMP-7, MMP-9, and MMP-13 
(R&D Systems, Inc., Minneapolis, MN), respectively. 
MMP-2, MMP-3, MMP-7, and MMP-13 enzymes were 
activated  by  incubation  with  2.5  mM  of 
p-aminophenyl mercuric acid in 0.1 % NaOH buffer 
for 1 h at 37
C prior to initiation of the assay. Fluo-
rescence intensity was measured using a spectroflu-
orometer  (F-7000  Fluorescence  Spectrophotometer, 
Hitach, Tokyo, Japan) 80min after incubation at 37
C. 
The  excitation  wavelength  was  set  at  675  nm  and 
emission spectra were recorded from 676 to 800 nm 
[20].  
Screening of MMP activity in SF from OA pa-
tients 
Ten-fold  diluted  SF  (100μl)  was  added  to  the 
MMP diagnostic kit and incubated for 1 h at 37
C for 
measurement  of  MMP  activity.  PBS  buffer  was  re-
garded  as  control.  Following  incubation,  the  MMP 
diagnostic kit was imaged using a 12-bit CCD camera 
(Kodak, Japan) equipped with a special C-mount lens 
and a Cy5.5 bandpass emission filter (680 to 720 nm; 
Omega Optical, Brattleboro, VT). Fluorescence inten-
sity was measured using a fluorescence spectrofluo-
rometer. 
Zymography and image analysis 
Five-fold  diluted  SF  (5μl)  was  mixed  with  an 
equal volume of sample buffer (10% sodium dodecyl 
sulfate,  0.5M  Tris  [pH  6.8],  and  5%  [v/v]  glycerol 
containing 0.1% [w/v] bromphenol blue). For gelain 
zymography,  the  SF  sample  was  loaded  on  a  10% 
polyacrylamide gel containing copolymerized gelatin 
(1mg/ml).  The  gel  was  washed  two  times  in  2.5% 
(v/v) Triton X-100 (30min and 1h each) and incubated 
in  50mM  Tris  HCl,  pH  7.5,  0.2M  NaCl,  and  10mM 
CaCl2 at 37
C for 24h. The gel was stained with 3% 
Coomassie  blue  and  destained.  MMP  activity  was 
revealed as clear bands on a dark background of uni-
form light blue staining for comparison of gelatinase 
molecular weight standards [21]. After development, 
gel  images  were  captured  using  DNR  MiniBIS  pro 
(Bio-imaging systems). 
Protein electrophoresis and Western blotting  
SF (30μl) mixed with sample buffer (0.8% sodi-
um  dodecyl  sulfate,  0.25M  Tris  [pH  6.8],  and  10% 
[v/v]  glycerol  containing  0.05%  [w/v]  bromphenol 
blue) (final dilution of SF: 15-fold) ran on 7.5% poly-
acrylamide gel after 10 min of boiling. Gels were then 
transferred  to  a  blotting  membrane  using  iBLOT 
(Invitrogen). Membranes were blocked with 5% low 
fat dry milk in Tris bufferd saline-Tween20 (TBST) for 
1h at room temperature (RT), followed by incubation 
with  primary  antibody  (anti-MMP-13  [Calbiochem, 
1:400] at RT for 1h. Thereafter, 3 washes (15 min each) 
with  TBST  were  performed  and  membranes  were 
incubated with a 1/2000 dilution of horseradish pe-
roxidase-conjugated anti-mouse antibody (Waters) in 
TBST  for  30  min,  followed  by  further  washings  (3 
washes,  15min.  each)  with  TBST.  Immunoreactive 
proteins were visualized using enhanced chemilumi-
nescence (Pierce). Theranostics 2012, 2(2) 
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Statistical Analyses  
Data were obtained from triplicate samples and 
expressed as mean  ± standard deviations.  One-way 
analysis of variance (ANOVA) was used for compar-
ison of continuous variables between groups. A value 
of p<0.05 was considered statistically significant.  
Results 
The  MMP  diagnostic  kit  was  fabricated  for 
high-throughput screening of MMP-2, -9, and -13 bi-
oactivity in SF samples of OA patients in a rapid and 
easy fashion (Fig. 1A). The principle of the MMP di-
agnostic kit is based upon recovery of quenched flu-
orescence by cleavage of specific substrate peptides. 
Once target enzymes, such as MMPs, cleave specific 
substrate peptides, the fluorophore becomes accessi-
ble for detection. Fluorescence intensity of the result-
ing product correlating with MMP activity is meas-
ured [16]. 
 
 
Figure 1. (A) Schematic diagram of the MMP diagnostic kit for rapid and easy detection of MMP activity. When MMP-2, 9, 13 were simply 
added and incubated in the MMP diagnostic kit, the fluorescence of each well was recovered and the fluorescence intensity showed 
distinct differences within minutes through the NIR fluorescence imaging system. (B) Fluorescence intensity of polymer-conjugated MMP 
peptide probe in solution (20 nM) in the presence of various stimuli (MMP-2, -3, -7, -9, -13) for 80 min at 37 C. 
 Theranostics 2012, 2(2) 
 
http://www.thno.org 
202 
Table 1. Characteristics of the patients and their knees. Results are shown as mean (SD), (median), and range 
Sex (F/M*)  Age (years)  Disease Duration (years)  Aspirated SF* volume (ml)  Disease (Acute*/OA)  Grading Scale 
(1/2/3/4) 
33/5  57.6 (15.3)  4.63 (6.85)  5.8 (6.4)  5/33  9/12/6/11 
  (60.5)  (6.5)  (3.0)     
  19-84  0-30  0.1-30     
*F=female; M-male; SF=synovial fluid; Acute=acute inflammatory conditions of the knee joints. 
 
 
 
Figure 2. X-ray data from patients with OA (grades 1 – 4) and acute inflammatory conditions of the knee joints. 
 
 
For preparation of a high-throughput MMP di-
agnostic  kit,  first,  the  MMP  peptide  probe,  which 
consisted  of  NIR  fluorophore,  MMP  substrate  pep-
tide, and black hole quencher, was chemically conju-
gated to glycol chitosan (GC) polymer, in the resulting 
polymer-conjugated  MMP  peptide  probe.  Second, 
polymer-conjugated MMP peptide probes were effec-
tively  immobilized  onto  each  well  of  maleic  anhy-
dride-activated 96-well plates, in the resulting MMP 
diagnostic kit. The polymer-conjugated MMP probe 
clearly demonstrated that significant recovery of flu-
orescence signals occurred against MMP-2, -9, and -13 
(11.1±0.72, 8.6±1.5, and 14.1±1.6-folds for MMP-2, -9, 
and  -13,  respectively)  (Fig.  1B).  A  small  amount  of 
recovered fluorescent intensity occurred in the poly-
mer-conjugated MMP probe treated by MMP-3 and 
MMP-7 80 min after incubation at 37
C.  
Among a total of 38 OA patients enrolled in this 
study, there were 33 females and 5 males (Table 1). 
The mean age was approximately 57.6 years and the 
mean disease duration was 4.63 years. Knee OA was 
diagnosed  by  clinical  and  radiological  evaluations 
and divided into four groups according to the severity 
of OA based on the Kellgren–Lawrence radiographic 
grading scale, which emphasizes joint space narrow-
ing and significance of osteophytes (grades 1 - 4, with 
1 being early stage of OA and 4 severe OA). As OA 
progresses,  the  medial  compartment  becomes  nar-
rower  and  the  lateral  compartment  becomes  wider. 
There  are  also  a  number  of  osteophytes  and  large 
subchrondral cysts where the bones rubbed together. 
Early stages of OA are easy to distinguish from late 
stages of OA through X-rays (Fig. 2). However, dif-
ferentiation  between  early  stage  OA  and  acute  in-
flammatory conditions of the knee joint only through 
radiological evaluation is difficult. In fact, based on 
the radiologic findings, all 38 patients were initially 
diagnosed as OA combined with variable amounts of 
joint  effusion.  However,  through  further  laboratory 
and diagnostic imaging studies, including MRI, 5 pa-
tients were finally diagnosed with acute inflammatory 
conditions of the knee joint, which can be combined 
with joint effusion. 
The MMP diagnostic kit was used for detection 
of MMP activity in SF from all 38 patients (Fig. 3A). 
When the 10-fold diluted SF (100 l) was simply in-
cubated in the MMP diagnostic kit at 37C, each well 
showed  distinct  NIR  fluorescent  signal  differences 
after 1 hour post-incubation. Recovered NIR fluores-
cent signals were not dependent on OA severity, in-
dicating that MMP activity in SF does not correspond 
to OA grade. Importantly, SF from patients with acute 
inflammatory conditions of the knee joint presented 
stronger  NIR  fluorescent  signals,  compared  to  OA Theranostics 2012, 2(2) 
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patients, wherein a 3.8-fold increase in NIR fluores-
cent signals was observed (Fig. 3B). Median levels of 
recovery fluorescence signals were as follows: OA 127 
(range from 21 to 238) and acute inflammatory condi-
tions of the knee joints 483 (range from 247 to 679). 
Recovery fluorescence signals in the group with acute 
inflammatory conditions of the knee joint were sig-
nificantly higher (p<0.05) than in the OA group.  
 
 
 
Figure 3. (A) NIR fluorescent image of the MMP diagnostic kit treated with SF samples from patients with OA and acute inflammatory 
conditions of the knee joints. Sample number 3, 5, 9, 13, and 21 are SF samples from patients with acute inflammatory conditions of the 
knee joints and C indicates the well treated with PBS as control. (B) upper: Number of SF samples treated in (A). lower: Fluorescent 
intensity of the MMP diagnostic kit treated with SF samples from patients with OA and acute inflammatory conditions of the knee joints. 
Boxes show the median as well as the 25th and 75th percentiles, while whiskers indicate the 10th and 90th percentiles. Each circle represents 
an outlier. SF samples from 4 OA patients (lanes 2, 4-6) and 3 patients with acute inflammatory conditions of the knee joints (lanes 1, 3, 
7) analyzed by (C) gelatin zymography and (D) Western blotting using the MMP-13 antibody. The positions of MMP-2 and MMP-9 are 
shown. Precision Plus Protein Standards (Bio-rad) were used as molecular size markers (data not shown). Sample number 3, 5, and 9 are 
SF samples from patients with acute inflammatory conditions of the knee joints. 
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To measure amounts of individual MMP in SF 
from patients, gelatin zymography and Western blot-
ting  using  the  MMP-13  antibody  were  performed. 
Results of gelatin zymography revealed MMP activity 
at 72 kDa and 92 kDa (Fig. 3C). MMP activity at 72 
kDa and 92 kDa has been known to represent MMP-2 
and MMP-9, respectively [22]. The presence of MMP-2 
in all samples without clear differences in band in-
tensities  may  represent  constitutive  expression  of 
MMP-2.  Most  samples  from  patients  with  acute  in-
flammatory conditions of the knee joint also displayed 
92 kDa (pro-form) MMP-9 and faint 84 kDa (active 
form)  MMP-9,  while  SF  from  OA  patients  did  not 
display detectable MMP-9 activity. SF samples were 
subjected to Western blotting using the MMP-13 an-
tibody.  Results  of  Western  blotting  indicated  that 
MMP-13 was detectable in all of the SF from patients 
with  OA  and  acute  inflammatory  conditions  of  the 
knee joint. The presence of a strong fluorescence sig-
nal from the MMP diagnostic kit corresponded well 
with patients with acute inflammatory conditions of 
the knee joint. The results suggest that our MMP di-
agnostic kit can be useful in differentiation between 
early stages of OA and acute inflammatory conditions 
of the knee joint. 
Discussion 
Detection of MMP activity in biological samples 
provides important information for diagnosis, prog-
nosis, and therapeutic monitoring of various diseases. 
For high throughput screening, rapid and continuous 
measurement is advantageous. In the current study, 
we have used  the MMP diagnostic kit containing  a 
polymer-conjugated  MMP  probe  immobilized  on  a 
96-well  plate  for  detection  of  MMP  activity  in  SF 
samples from patients with OA and acute inflamma-
tory  conditions  of  the  knee  joint.  Compared  to  SF 
from  OA  patients,  SF  from  patients  with  acute  in-
flammatory  conditions  of  the  knee  joints  presented 
stronger  NIR  fluorescent  signals.  Measurement  of 
active MMP using our MMP diagnostic kit could be 
useful in discriminating between early stages of OA 
and acute inflammatory conditions of the knee joint in 
a rapid and easy fashion. Also, this technology could 
be  clinically  applicable  in  diagnosing  whether  joint 
effusion is caused by primary OA or by inflammation 
secondary to other disease entities. 
SF from patients with acute inflammatory con-
ditions of the knee joint emitted noticeable NIR fluo-
rescent  signals,  compared  to  those  of  primary  OA 
patients.  Comparing  NIR  fluorescent  signals  in  the 
MMP diagnostic kit and zymography/Western blot-
ting, expression of MMP-2 and -13 might be respon-
sible for background signals in the SF sample; how-
ever,  MMP-9  appears to be one of  the main MMPs 
expressed in cases of acute inflammatory conditions 
of  the  knee  joints.  We  found  statistically  enhanced 
fluorescent signals in SF samples from the group with 
acute  inflammatory  conditions  of  the  knee  joint, 
compared to the OA group. We also found that fluo-
rescent  signals  in  SF  samples  from  patients  whose 
disease  duration  was  less  than  2  years  (222  ±  158) 
were stronger than those from patients whose disease 
duration exceeded 2 years (94.0 ± 35.2) (Fig. 4).  
 
 
 
Figure 4. Fluorescent intensity of the MMP diagnostic kit treated 
with SF samples from patients whose disease duration is greater 
than and less than 2 years. Boxes show the median as well as the 
25th and 75th percentiles, while whiskers indicate the 10th and 90th 
percentiles. Each circle represents an outlier. 
 
 
SF is closer to the location of joint cartilage and 
protease  degradation  than  serum  or  urine,  and, 
therefore, could emit better local pathologic processes 
in the joint [23]. When SF aspiration was attempted 
from the knee joints of patients, it was found that as-
pirated SF samples varied in their viscosity and vol-
ume.  In  our  experimental  setup,  small  amounts  of 
harvested  SF  (10  μl)  were  applied  to  measure  the 
concentration of MMP from the harvested SF sample; 
however, this method  had limitations in presenting 
the total protein amount involved in biological activi-
ties in the joint. Therefore, estimation of SF volume for 
determination of total amounts of MMP in the joint 
would be desirable. Several studies have reported on 
possible  methods  for  estimation  of  SF  volume  with 
radioisotopic  dilution  techniques  that  include 
[113In]-indium chloride or sodium [99Tc]-pertechnetate 
and  a non-radioactive method based upon albumin 
dilution  upon  intra-articular  injection  of  saline  [24]. 
Considering estimated SF volume to NIR fluorescent Theranostics 2012, 2(2) 
 
http://www.thno.org 
205 
signals in the MMP diagnostic kit, the concentration 
of  active  MMP  in  the  SF  might  be  calculated  with 
greater accuracy.  
In this study, MMP acts as a biological marker 
for OA. Biological OA markers may allow detection of 
early  and  subtle  changes  in  tissue  at  the  molecular 
level. In addition to MMP, there are other proteases 
that may also be involved in the pathogenesis of OA, 
and can serve as biomarkers. For example, cathepsin 
and aggrecanase are known to play key roles in carti-
lage degradation. The diagnostic kit can be extended 
to  other  proteases,  such  as  aggrecanase,  simply  by 
changing the specific peptide substrate linker between 
the fluorophore and black hole quencher. In addition, 
because MMPs are a homologous family of enzymes 
that  possess  high  sequence  similarity  and  similar 
three-dimensional structures, our MMP probe used in 
this diagnostic kit is specific to MMP-2, -9, and -13 
[25]. These properties may hamper MMP probes that 
are  designed  for  high  sensitivity  and  specificity  to 
certain  diseases  over-expressing  certain  MMPs.  To 
overcome this drawback, the use of multi-probes, in-
cluding more than one MMP substrate sequence, may 
enhance sensitivity and specificity for certain types of 
MMPs.  
In  summary,  we  detected  MMP  activity  in  a 
large number of SF samples from patients with OA 
and acute inflammatory conditions of the knee joint 
using  the  MMP  diagnostic  kit  containing  a  poly-
mer-conjugated MMP probe immobilized on a 96-well 
plate in a rapid and easy fashion. The MMP diagnostic 
kit  may  be  useful  in  discriminating  between  early 
stages of OA and acute  inflammatory conditions of 
the knee joint, which can be difficult to tell apart if the 
diagnosis  is  made  only  based  on  morphological 
changes of the knee joints that appear on X-rays. Our 
diagnostic kit was also applied for detection of MMP 
activity in various biological samples, such as blood 
serum from rheumatoid arthritis patients. In addition, 
it can be utilized to distinguish pre-clinical diseases 
related  to  MMPs  and  in  assessment  of  individual 
therapeutic monitoring  of drug treatments and sur-
gical therapy in a rapid and easy fashion.  
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